Skip to main content
Top
Published in: Endocrine 3/2018

01-06-2018 | Endocrine Methods and Techniques

A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms

Authors: Ivan Kruljac, Ivan Vurnek, Sebastian Maasberg, Davor Kust, Kristina Blaslov, Blaženka Ladika Davidović, Mario Štefanović, Alma Demirović, Alen Bišćanin, Jakša Filipović-Čugura, Jasmina Marić Brozić, Ulrich-Frank Pape, Milan Vrkljan

Published in: Endocrine | Issue 3/2018

Login to get access

Abstract

Background

Chromogranin A (CgA) is a valuable biomarker for detection and follow-up of patients with neuroendocrine neoplasms (NENs). However, various comorbidities may influence serum CgA, which decreases its diagnostic accuracy. We aimed to investigate which laboratory parameters are independently associated with increased CgA in real-life setting and to develop a scoring system, which could improve the diagnostic accuracy of CgA in detecting patients with NENs.

Methods

This retrospective study included 55 treatment naïve patients with NENs and160 patients with various comorbidities but without NEN (nonNENs). Scoring system (CgA-score) was developed based on z-scores obtained from receiver operating curve analysis for each parameter that was associated with elevated serum CgA in nonNENs.

Results

CgA correlated positively with serum BUN, creatinine, α2-globulin, red-cell distribution width, erythrocyte sedimentation rate, plasma glucose and correlated inversely with hemoglobin, thrombocytes and serum albumin. Serum CgA was also associated with the presence of chronic renal failure, arterial hypertension and diabetes and the use of PPI. In the entire study population, CgA showed an area under the curve of 0.656. Aforementioned parameters were used to develop a CgA-score. In a cohort of patients with CgA-score <12.0 (N = 87), serum CgA >156.5 ng/ml had 77.8% sensitivity and 91.5% specificity for detecting NENs (AUC 0.841, 95% CI 0.713–0.969, P < 0.001). Serum CgA had no diagnostic value in detecting NENs in patients with CgA-score >12.0 (AUC 0.554, 95% CI 0.405–0.702, P = 0.430).

Conclusions

CgA-score encompasses a wide range of comorbidities and represents a promising tool that could improve diagnostic performance of CgA in everyday clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference L. Taupenot, K.L. Harper, D.T. O’Connor, The chromogranin–secretogranin family. N. Engl. J. Med. 348, 1134–1149 (2003)CrossRefPubMed L. Taupenot, K.L. Harper, D.T. O’Connor, The chromogranin–secretogranin family. N. Engl. J. Med. 348, 1134–1149 (2003)CrossRefPubMed
2.
3.
go back to reference D. Belloni, S. Scabini, C. Foglieni, L. Veschini, A. Giazzon, B. Colombo et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. Faseb. J. 21, 3052–3062 (2007)CrossRefPubMed D. Belloni, S. Scabini, C. Foglieni, L. Veschini, A. Giazzon, B. Colombo et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. Faseb. J. 21, 3052–3062 (2007)CrossRefPubMed
4.
go back to reference E. Ferrero, S. Scabini, E. Magni, C. Foglieni, D. Belloni, B. Colombo et al. Chromogranin A protects vessels against tumor necrosis factor-induced vascular leakage. FASEB J. 18, 554–556 (2004)CrossRefPubMed E. Ferrero, S. Scabini, E. Magni, C. Foglieni, D. Belloni, B. Colombo et al. Chromogranin A protects vessels against tumor necrosis factor-induced vascular leakage. FASEB J. 18, 554–556 (2004)CrossRefPubMed
5.
go back to reference B. Tota, S. Gentile, T. Pasqua, E. Bassino, H. Koshimizu, N.X. Cawley et al. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes. FASEB J. Fed. Am. Soc. Exp. Biol. 26, 2888–2898 (2012)PubMed B. Tota, S. Gentile, T. Pasqua, E. Bassino, H. Koshimizu, N.X. Cawley et al. The novel chromogranin A-derived serpinin and pyroglutaminated serpinin peptides are positive cardiac β-adrenergic-like inotropes. FASEB J. Fed. Am. Soc. Exp. Biol. 26, 2888–2898 (2012)PubMed
6.
go back to reference V. Sánchez-Margalet, C. González-Yanes, S. Najib, J. Santos-Álvarez, Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul. Pept. 161, 8–14 (2010)CrossRefPubMed V. Sánchez-Margalet, C. González-Yanes, S. Najib, J. Santos-Álvarez, Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin. Regul. Pept. 161, 8–14 (2010)CrossRefPubMed
7.
go back to reference M.M. Fung, R.M. Salem, P. Mehtani, B. Thomas, C.F. Lu, B. Perez et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin. Exp. Hypertens. 32, 278–287 (2010)CrossRefPubMedPubMedCentral M.M. Fung, R.M. Salem, P. Mehtani, B. Thomas, C.F. Lu, B. Perez et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin. Exp. Hypertens. 32, 278–287 (2010)CrossRefPubMedPubMedCentral
8.
go back to reference D. Zhang, T. Lavaux, A.-C. Voegeli, T. Lavigne, V. Castelain, N. Meyer et al. Prognostic value of chromogranin a at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin. Chem. 54, 1497–1503 (2008)CrossRefPubMed D. Zhang, T. Lavaux, A.-C. Voegeli, T. Lavigne, V. Castelain, N. Meyer et al. Prognostic value of chromogranin a at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin. Chem. 54, 1497–1503 (2008)CrossRefPubMed
9.
go back to reference G. Di Comite, C.M. Rossi, A. Marinosci, K. Lolmede, E. Baldissera, P. Aiello et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF- -elicited endothelial activation. J. Leukoc. Biol. 85, 81–87 (2008)CrossRefPubMed G. Di Comite, C.M. Rossi, A. Marinosci, K. Lolmede, E. Baldissera, P. Aiello et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF- -elicited endothelial activation. J. Leukoc. Biol. 85, 81–87 (2008)CrossRefPubMed
10.
go back to reference V. Sciola, S. Massironi, D. Conte, F. Caprioli, S. Ferrero, C. Ciafardini et al. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15, 867–871 (2009)CrossRefPubMed V. Sciola, S. Massironi, D. Conte, F. Caprioli, S. Ferrero, C. Ciafardini et al. Plasma chromogranin a in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15, 867–871 (2009)CrossRefPubMed
11.
go back to reference A. Zissimopoulos, S. Vradelis, M. Konialis, D. Chadolias, A. Bampali, T. Constantinidis et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand. J. Gastroenterol. 49, 942–949 (2014)CrossRefPubMed A. Zissimopoulos, S. Vradelis, M. Konialis, D. Chadolias, A. Bampali, T. Constantinidis et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand. J. Gastroenterol. 49, 942–949 (2014)CrossRefPubMed
12.
go back to reference P. Gut, A. Czarnywojtek, J. Fischbach, M. Bączyk, K. Ziemnicka, E. Wrotkowska et al. Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch. Med. Sci. Terme. Publ. 12, 1–9 (2016) P. Gut, A. Czarnywojtek, J. Fischbach, M. Bączyk, K. Ziemnicka, E. Wrotkowska et al. Chromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch. Med. Sci. Terme. Publ. 12, 1–9 (2016)
13.
go back to reference P.R. Bech, R. Ramachandran, W.S. Dhillo, N.M. Martin, S.R. Bloom, Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine and amphetamine-regulated transcript. Clin. Chem. 58, 941–943 (2012).CrossRefPubMed P.R. Bech, R. Ramachandran, W.S. Dhillo, N.M. Martin, S.R. Bloom, Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine and amphetamine-regulated transcript. Clin. Chem. 58, 941–943 (2012).CrossRefPubMed
14.
go back to reference C. Ceconi, R. Ferrari, T. Bachetti, C. Opasich, M. Volterrani, B. Colombo et al. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23, 967–974 (2002)CrossRefPubMed C. Ceconi, R. Ferrari, T. Bachetti, C. Opasich, M. Volterrani, B. Colombo et al. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23, 967–974 (2002)CrossRefPubMed
15.
go back to reference M.E. Estensen, A. Hognestad, U. Syversen, I. Squire, L. Ng, J. Kjekshus et al.Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am. Heart J. 152, 927.e1–927.e6 (2006)CrossRef M.E. Estensen, A. Hognestad, U. Syversen, I. Squire, L. Ng, J. Kjekshus et al.Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am. Heart J. 152, 927.e1–927.e6 (2006)CrossRef
16.
go back to reference M.A. Takiyyuddin, R.J. Parmer, M.T. Kailasam, J.H. Cervenka, B. Kennedy, M.G. Ziegler et al., Chromogranin A in human hypertension. Hypertension 26, 213–220 (1995).CrossRefPubMed M.A. Takiyyuddin, R.J. Parmer, M.T. Kailasam, J.H. Cervenka, B. Kennedy, M.G. Ziegler et al., Chromogranin A in human hypertension. Hypertension 26, 213–220 (1995).CrossRefPubMed
17.
go back to reference M. Peracchi, C. Gebbia, G. Basilisco, M. Quatrini, C. Tarantino, C. Vescarelli et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur. J. Endocrinol. 152, 443–448 (2005)CrossRefPubMed M. Peracchi, C. Gebbia, G. Basilisco, M. Quatrini, C. Tarantino, C. Vescarelli et al. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. Eur. J. Endocrinol. 152, 443–448 (2005)CrossRefPubMed
18.
go back to reference I. Pregun, L. Herszényi, M. Juhász, P. Miheller, I. Hritz, A. Patócs et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 84, 22–28 (2011)CrossRefPubMed I. Pregun, L. Herszényi, M. Juhász, P. Miheller, I. Hritz, A. Patócs et al. Effect of proton-pump inhibitor therapy on serum chromogranin a level. Digestion 84, 22–28 (2011)CrossRefPubMed
19.
go back to reference K. Oberg, A. Couvelard, G. Delle Fave, D. Gross, A. Grossman, R.T. Jensen et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology 105, 201–211 (2017)CrossRefPubMed K. Oberg, A. Couvelard, G. Delle Fave, D. Gross, A. Grossman, R.T. Jensen et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers. Neuroendocrinology 105, 201–211 (2017)CrossRefPubMed
20.
go back to reference S. Welin, M. Stridsberg, J. Cunningham, D. Granberg, B. Skogseid, B. Eriksson et al. Elevated plasma chromogranin a is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 89, 302–307 (2009)CrossRefPubMed S. Welin, M. Stridsberg, J. Cunningham, D. Granberg, B. Skogseid, B. Eriksson et al. Elevated plasma chromogranin a is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 89, 302–307 (2009)CrossRefPubMed
21.
go back to reference J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, P. Ruszniewski et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. 28, 69–76 (2010)CrossRefPubMed J.C. Yao, C. Lombard-Bohas, E. Baudin, L.K. Kvols, P. Rougier, P. Ruszniewski et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J. Clin. Oncol. 28, 69–76 (2010)CrossRefPubMed
22.
go back to reference B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin a as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40, 111–134 (2011)CrossRefPubMed B. Lawrence, B.I. Gustafsson, M. Kidd, M. Pavel, B. Svejda, I.M. Modlin, The clinical relevance of chromogranin a as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40, 111–134 (2011)CrossRefPubMed
23.
go back to reference V. Marotta, V. Nuzzo, T. Ferrara, A. Zuccoli, M. Masone, L. Nocerino et al. Limitations of Chromogranin A in clinical practice. Biomarkers 17(2), 186–191 (2012)CrossRefPubMed V. Marotta, V. Nuzzo, T. Ferrara, A. Zuccoli, M. Masone, L. Nocerino et al. Limitations of Chromogranin A in clinical practice. Biomarkers 17(2), 186–191 (2012)CrossRefPubMed
24.
go back to reference S. Nölting, A. Kuttner, M. Lauseker, M. Vogeser, A. Haug, K.A. Herrmann et al. Chromogranin A as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 4, 141–155 (2012)CrossRef S. Nölting, A. Kuttner, M. Lauseker, M. Vogeser, A. Haug, K.A. Herrmann et al. Chromogranin A as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel) 4, 141–155 (2012)CrossRef
25.
go back to reference A. Tirosh, G.Z. Papadakis, C. Millo, S.M. Sadowski, P. Herscovitch, K. Pacak et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. Eur. J. Endocrinol. 176, 575–582 (2017)CrossRefPubMedPubMedCentral A. Tirosh, G.Z. Papadakis, C. Millo, S.M. Sadowski, P. Herscovitch, K. Pacak et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. Eur. J. Endocrinol. 176, 575–582 (2017)CrossRefPubMedPubMedCentral
26.
go back to reference M. Stridsberg, B. Eriksson, K. Oberg, E.T. Janson, A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol. 177, 337–341 (2003)CrossRefPubMed M. Stridsberg, B. Eriksson, K. Oberg, E.T. Janson, A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol. 177, 337–341 (2003)CrossRefPubMed
27.
go back to reference P. Glinicki, R. Kapuścińska, W. Jeske, Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays: the importance of protein matrix effects. Clin. Endocrinol. (Oxf.). 79, 295–296 (2013)CrossRefPubMed P. Glinicki, R. Kapuścińska, W. Jeske, Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays: the importance of protein matrix effects. Clin. Endocrinol. (Oxf.). 79, 295–296 (2013)CrossRefPubMed
28.
go back to reference M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95, 157–176 (2012)CrossRefPubMed M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg, T. Steinmüller et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95, 157–176 (2012)CrossRefPubMed
30.
go back to reference I.M. Modlin, I. Drozdov, D. Alaimo, S. Callahan, N. Teixiera, L. Bodei et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr. Relat. Cancer 21, 615–628 (2014)CrossRefPubMed I.M. Modlin, I. Drozdov, D. Alaimo, S. Callahan, N. Teixiera, L. Bodei et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr. Relat. Cancer 21, 615–628 (2014)CrossRefPubMed
31.
go back to reference I.M. Modlin, M. Kidd, L. Bodei, I. Drozdov, H. Aslanian, The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am. J. Gastroenterol. 110, 1223–1232 (2015)CrossRefPubMed I.M. Modlin, M. Kidd, L. Bodei, I. Drozdov, H. Aslanian, The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am. J. Gastroenterol. 110, 1223–1232 (2015)CrossRefPubMed
32.
go back to reference S. Massironi, M. Fraquelli, S. Paggi, A. Sangiovanni, D. Conte, V. Sciola et al. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig. Liver. Dis. 41, 31–35 (2009)CrossRefPubMed S. Massironi, M. Fraquelli, S. Paggi, A. Sangiovanni, D. Conte, V. Sciola et al. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig. Liver. Dis. 41, 31–35 (2009)CrossRefPubMed
33.
go back to reference S. Doğan, N. Atakan, Red blood cell distribution width is a reliable marker of inflammation in plaque psoriasis. Acta Dermatovenerol. Croat. 25, 26–31 (2017)PubMed S. Doğan, N. Atakan, Red blood cell distribution width is a reliable marker of inflammation in plaque psoriasis. Acta Dermatovenerol. Croat. 25, 26–31 (2017)PubMed
34.
go back to reference V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES. Int. J. Cardiol. 168, 5156–5161 (2013)CrossRefPubMed V. Veeranna, S.K. Zalawadiya, S. Panaich, K.V. Patel, L. Afonso, Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES. Int. J. Cardiol. 168, 5156–5161 (2013)CrossRefPubMed
35.
go back to reference Z.-D. Hu, Y. Chen, L. Zhang, Y. Sun, Y.-L. Huang, Q.-Q. Wang et al. Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus. Clin. Chim. Acta 425, 202–205 (2013)CrossRefPubMed Z.-D. Hu, Y. Chen, L. Zhang, Y. Sun, Y.-L. Huang, Q.-Q. Wang et al. Red blood cell distribution width is a potential index to assess the disease activity of systemic lupus erythematosus. Clin. Chim. Acta 425, 202–205 (2013)CrossRefPubMed
36.
go back to reference N.S. Ku, H. Kim, H.J. Oh, Y.C. Kim, M.H. Kim, J.E. Song et al. Red blood cell distribution width is an independent predictor of mortality in patients with gram-negative bacteremia. Shock 38, 123–127 (2012)CrossRefPubMed N.S. Ku, H. Kim, H.J. Oh, Y.C. Kim, M.H. Kim, J.E. Song et al. Red blood cell distribution width is an independent predictor of mortality in patients with gram-negative bacteremia. Shock 38, 123–127 (2012)CrossRefPubMed
37.
go back to reference J.H. Lee, H.J. Chung, K. Kim, Y.H. Jo, J.E. Rhee, Y.J. Kim et al. Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia. Am. J. Emerg. Med. 31, 72–79 (2013)CrossRefPubMed J.H. Lee, H.J. Chung, K. Kim, Y.H. Jo, J.E. Rhee, Y.J. Kim et al. Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia. Am. J. Emerg. Med. 31, 72–79 (2013)CrossRefPubMed
38.
go back to reference T. Isakova, P. Wahl, G.S. Vargas, O.M. Gutiérrez, J. Scialla, H. Xie et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370–1378 (2011)CrossRefPubMedPubMedCentral T. Isakova, P. Wahl, G.S. Vargas, O.M. Gutiérrez, J. Scialla, H. Xie et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370–1378 (2011)CrossRefPubMedPubMedCentral
39.
40.
go back to reference R.F. Ritchie, G.E. Palomaki, L.M. Neveux, O. Navolotskaia, T.B. Ledue, W.Y. Craig, Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort. J. Clin. Lab. Anal. 18, 139–147 (2004)CrossRefPubMed R.F. Ritchie, G.E. Palomaki, L.M. Neveux, O. Navolotskaia, T.B. Ledue, W.Y. Craig, Reference distributions for alpha2-macroglobulin: a practical, simple and clinically relevant approach in a large cohort. J. Clin. Lab. Anal. 18, 139–147 (2004)CrossRefPubMed
42.
go back to reference Y. Wang, Q. Yang, Y. Lin, L. Xue, M. Chen, J. Chen, Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine. (Baltim.). 93, e247 (2014)CrossRef Y. Wang, Q. Yang, Y. Lin, L. Xue, M. Chen, J. Chen, Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine. (Baltim.). 93, e247 (2014)CrossRef
43.
go back to reference S. Massironi, R.E. Rossi, G. Casazza, D. Conte, C. Ciafardini, M. Galeazzi et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology 100, 240–249 (2014)CrossRefPubMed S. Massironi, R.E. Rossi, G. Casazza, D. Conte, C. Ciafardini, M. Galeazzi et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology 100, 240–249 (2014)CrossRefPubMed
Metadata
Title
A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms
Authors
Ivan Kruljac
Ivan Vurnek
Sebastian Maasberg
Davor Kust
Kristina Blaslov
Blaženka Ladika Davidović
Mario Štefanović
Alma Demirović
Alen Bišćanin
Jakša Filipović-Čugura
Jasmina Marić Brozić
Ulrich-Frank Pape
Milan Vrkljan
Publication date
01-06-2018
Publisher
Springer US
Published in
Endocrine / Issue 3/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1592-6

Other articles of this Issue 3/2018

Endocrine 3/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.